MedTrace Logo

The Effects of Unfiltered (Turkish) Coffee Consumption on Cardiovascular Risk Parameters

NCT03495336 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2018-04-12

No results posted yet for this study

Summary

Purpose/Objective: The aim of this study is to investigate the impact of boiled unfiltered (Turkish) coffee consumption on the plasma cardiovascular risk parameters of healthy subjects. The study also explores whether two unfiltered boiled (Turkish) coffee beverages that differ in content due to different roasting degrees will differentially affect cardiovascular biomarkers.

Methods: In this crossover intervention study, healthy, nonsmoking, habitual Turkish coffee drinkers (n=28) were randomized to consume at least 3 cups of Light (LR) or Dark (DR) roast Turkish coffee brews per day for 4 weeks after a washout period (WO) of 2 weeks. Subsequent to each coffee abstinence period, both groups received the alternative intervention. After the first WO and the coffee intervention periods, anthropometric measures, blood pressure, heart rate and 13 biochemical parameters were collected and dietary records were completed.

Conditions

Interventions

OTHER

coffee abstention phase

no coffee consumption for 2 weeks

OTHER

LR Coffee consumption

for 4 weeks participants consumed only LR Turkish coffee

OTHER

DR Coffee consumption

for 4 weeks participants consumed only DR Turkish coffee

Sponsors & Collaborators

  • Eastern Mediterranean University

    lead OTHER

Principal Investigators

  • Tanju Besler, Prof. · Eastern Mediterranean University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-22
Primary Completion
2017-06-22
Completion
2017-10-22

Countries

  • Cyprus

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03495336 on ClinicalTrials.gov